TY - JOUR T1 - Changes in transmission of Enterovirus D68 (EV-D68) in England inferred from seroprevalence data JF - medRxiv DO - 10.1101/2021.11.08.21265913 SP - 2021.11.08.21265913 AU - Margarita Pons-Salort AU - Ben Lambert AU - Everlyn Kamau AU - Richard Pebody AU - Heli Harvala AU - Peter Simmonds AU - Nicholas C Grassly Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/09/2021.11.08.21265913.abstract N2 - The factors leading to the global emergence of enterovirus D68 (EV-D68) in 2014 as a cause of acute flaccid myelitis (AFM) in children are unknown. To investigate potential changes in virus transmissibility or population susceptibility, we measured the seroprevalence of EV-D68-specific neutralising antibodies in serum samples collected in England in 2006, 2011 and 2017. Using catalytic mathematical models, we estimate an approximately two-fold increase in the basic reproduction number over the 10-year study period, coinciding with the emergence of clade B around 2009. Despite such increase in transmission, the virus was already widely circulating before the AFM outbreaks and the increase of infections by age cannot explain the observed number of AFM cases. Therefore, the acquisition of or an increase in neuropathogenicity would be additionally required to explain the emergence of outbreaks of AFM. Our results provide evidence that changes in enterovirus phenotypes cause major changes in disease epidemiology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.P.-S. is a Sir Henry Dale Fellow jointly funded by the Wellcome Trust and the Royal Society (grant number 216427/Z/19/Z). M.P.-S. and N.C.G. acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. Work in P.S.'s lab was supported by a Wellcome ISSF grant (ISSF204826/Z/16/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Seroepidemiology Unit (SEU) Steering Committee of Public Health England (PHE) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -